174 related articles for article (PubMed ID: 11594583)
21. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.
Xerri L; Adélaïde J; Avenin M; Guille A; Taix S; Bonnet N; Carbuccia N; Garnier S; Mescam L; Murati A; Chaffanet M; Coso D; Bouabdallah R; Bertucci F; Birnbaum D
Histopathology; 2019 Mar; 74(4):654-662. PubMed ID: 30393995
[TBL] [Abstract][Full Text] [Related]
22. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
[TBL] [Abstract][Full Text] [Related]
23. When you make a diagnosis of lymphomatoid papulosis (LYP), do you mean to imply that the patient has lymphoma? If not, what is it?
Am J Dermatopathol; 1995 Apr; 17(2):197-208. PubMed ID: 8600789
[No Abstract] [Full Text] [Related]
24. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
Liang X; Smoller BR; Golitz LE
J Cutan Pathol; 2002 Sep; 29(8):459-64. PubMed ID: 12207739
[TBL] [Abstract][Full Text] [Related]
25. Primary cutaneous CD30(+) lymphoproliferative disorders.
Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
[TBL] [Abstract][Full Text] [Related]
26. Large atypical cells of lymphomatoid papulosis are CD56-negative: a study of 18 cases.
Harvell J; Vaseghi M; Natkunam Y; Kohler S; Kim Y
J Cutan Pathol; 2002 Feb; 29(2):88-92. PubMed ID: 12150138
[TBL] [Abstract][Full Text] [Related]
27. Lymphomatoid papulosis with folliculotropism, eccrinotropism and neurotropism.
Ba W; Yang Y; Zhang Z; Wei X; Wang W; Zhao Z; Zheng L; Li C
J Cutan Pathol; 2018 Jul; 45(7):530-534. PubMed ID: 29660166
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily.
Paulli M; Berti E; Boveri E; Kindl S; Bonoldi E; Gambini C; Rosso R; Borroni G; Straccapansa V; Magrini U; DeCoteau JE; Krammer PH; Möller P; Kadin ME
Hum Pathol; 1998 Nov; 29(11):1223-30. PubMed ID: 9824099
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations.
Assaf C; Hirsch B; Wagner F; Lucka L; Grünbaum M; Gellrich S; Lukowsky A; Sterry W; Stein H; Dürkop H
J Invest Dermatol; 2007 Aug; 127(8):1898-904. PubMed ID: 17392826
[TBL] [Abstract][Full Text] [Related]
30. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma.
Yagi H; Tokura Y; Furukawa F; Takigawa M
J Invest Dermatol; 1996 Dec; 107(6):827-32. PubMed ID: 8941669
[TBL] [Abstract][Full Text] [Related]
31. Lymphomatoid papulosis type D: a newly described variant easily confused with cutaneous aggressive CD8-positive cytotoxic T-cell lymphoma.
Cardoso J; Duhra P; Thway Y; Calonje E
Am J Dermatopathol; 2012 Oct; 34(7):762-5. PubMed ID: 22688398
[TBL] [Abstract][Full Text] [Related]
32. Recurrent Oncogenic JAK and STAT Alterations in Cutaneous CD30-Positive Lymphoproliferative Disorders.
Maurus K; Appenzeller S; Roth S; Brändlein S; Kneitz H; Goebeler M; Rosenwald A; Geissinger E; Wobser M
J Invest Dermatol; 2020 Oct; 140(10):2023-2031.e1. PubMed ID: 32147503
[TBL] [Abstract][Full Text] [Related]
33. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
34. Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis.
Cordel N; Tressières B; D'Incan M; Machet L; Grange F; Estève É; Dalac S; Ingen-Housz-Oro S; Bagot M; Beylot-Barry M; Joly P;
Oncologist; 2016 Jan; 21(1):76-83. PubMed ID: 26668250
[TBL] [Abstract][Full Text] [Related]
35. Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis.
Marschalkó M; Gyöngyösi N; Noll J; Károlyi Z; Wikonkál N; Hársing J; Kuroli E; Csomor J; Matolcsy A; Sarolta K; Szepesi Á
J Cutan Pathol; 2016 Nov; 43(11):963-973. PubMed ID: 27461449
[TBL] [Abstract][Full Text] [Related]
36. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
37. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders.
Franchina M; Kadin ME; Abraham LJ
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1322-5. PubMed ID: 15894695
[TBL] [Abstract][Full Text] [Related]
38. [Lymphomatoid papulosis type C or transition to CD30+-T-cell lymphoma? A difficult differential diagnosis].
Plettenberg H; Neumann NJ; Ruzicka T; Megahed M
Hautarzt; 2003 Apr; 54(4):366-8. PubMed ID: 12669213
[TBL] [Abstract][Full Text] [Related]
39. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
Wieser I; Oh CW; Talpur R; Duvic M
J Am Acad Dermatol; 2016 Jan; 74(1):59-67. PubMed ID: 26518172
[TBL] [Abstract][Full Text] [Related]
40. Lymphomatoid papulosis associated with both severe hypereosinophilic syndrome and CD30 positive large T-cell lymphoma.
Granel B; Serratrice J; Swiader L; Horshowski N; Blaise D; Vey N; Metras D; Habib G; Disdier P; Weiller PJ
Cancer; 2000 Nov; 89(10):2138-43. PubMed ID: 11066056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
